Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Status: Recruiting
Phase:
Diagnosis: Lung Cancer
NCT ID: NCT01348126
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-357
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Conducting Institutions:
Dana-Farber Cancer Institute
Overall PI:
Geoffrey Shapiro, MD, PhD,
Dana-Farber Cancer Institute
Site-responsible Investigators:
Contacts:
Dana-Farber Cancer Institute:
Kelly Masone, 617-632-3383,
kmasone@partners.org
Eligibility Criteria
Inclusion Criteria:
- confirmed diagnosis of NSCLC
- Stage IIIB or IV NSCLC
- ECOG Performance Status 0 or 1
- Prior therapy defined as 1 prior systemic therapy for advanced disease
- measurable disease
- Radiologic evidence of disease progression following most recent prior treatment.
- Adequate hematologic, hepatic, renal function
Exclusion Criteria:
- Active or untreated CNS metastases
- Active malignancies other than NSCLC within the last 5 years with the exception of
adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or
squamous cell carcinoma of the skin
- Serious cardiac illness or medical conditions
- Pregnant or lactating women
- Uncontrolled intercurrent illness